Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
2022年11月8日 - 9:34PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of November 2022
(Report No. 2)
Commission file number: 001-38041
SCISPARC LTD.
(Translation of registrant’s name into English)
20 Raul Wallenberg Street, Tower A,
Tel Aviv 6971916 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):
CONTENTS
On November 7, 2022, SciSparc
Ltd. (the “Company”) issued a press release entitled “SciSparc Announced Positive
Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation.”
A copy of this press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.
On November 8, 2022, the Company
issued a press release entitled “SciSparc Gains Competitive Edge with Additional U.S. Patent Granted.” A copy of this press
release is furnished herewith as Exhibit 99.2 and incorporated by reference herein.
This Report of Foreign Private
Issuer on Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-266047,
File No. 333-233417 and File No. 333-248670) and on Form S-8 (File No. 333-225773) filed with the Securities and Exchange Commission to
be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed
or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
SciSparc Ltd. |
|
|
|
Date: November 8, 2022 |
By: |
/s/ Oz Adler |
|
|
Name: |
Oz Adler |
|
|
Title: |
Chief Executive Officer & Chief Financial Officer |
3
Therapix Biosciences (NASDAQ:TRPX)
過去 株価チャート
から 10 2024 まで 11 2024
Therapix Biosciences (NASDAQ:TRPX)
過去 株価チャート
から 11 2023 まで 11 2024